title: Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: A network meta-analysis.
abstract: We aimed to create hierarchies of the efficacy, acceptability and tolerability of eight atypical antipsychotics in the treatment of Chinese patients with acute schizophrenia.
  
  
  
  We systematically searched for RCT articles published between January 1st 2005 and December 31st 2014 in electronic databases (Medline, Pubmed, Embase, the Cochrane Library and ClinicalTrial.gov for studies in English and the China National Knowledge Infrastructure, Wan Fang, and VIP Information/Chinese Scientific Journals Database for studies in Chinese). The primary outcome was efficacy, as measured by the change of PANSS total score. Pairwise comparisons were performed using random-effects model by the Dersimonian-Laird method and network meta-analyses were performed in a Bayesian set.
  
  
  
  Sixty high-quality RCTs with 6418 participants were included. A pattern of superiority from olanzapine, paliperidone and amisulpride was seen in the primary outcome. Only paliperidone was found better than aripiprazole (odds ratio, 0.49 [95% credible intervals, 0.25 to 0.99]), ziprasidone (0.42 [0.21 to 0.85]) and quetiapine (0.36 [0.13 to 0.93]) in terms of all-cause discontinuation. The best and worst drugs in terms of weight gain, EPS and somnolence were aripiprazole and olanzapine, clozapine and amisulpride, aripiprazole and clozapine, respectively. The rank of efficacy did not change substantially in sensitivity analyses or in meta-regressions.
  
  
  
  Our findings provided the hierarchies of eight antipsychotics in efficacy, acceptability and tolerability. These findings are expected to help Chinese clinicians to select the appropriate antipsychotic drug for their patients.
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China.
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Bai
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China.
authors.forename: Guoqiang
authors.initials: G
authors.lastname: Wang
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China.
authors.forename: Shangli
authors.initials: S
authors.lastname: Cai
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China.
authors.forename: Xindi
authors.initials: X
authors.lastname: Ding
authors.affiliation: Consulting Center of Biomedical Statistics, Beijing, People's Republic of China.
authors.forename: Weiwei
authors.initials: W
authors.lastname: Liu
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China.
authors.forename: Depei
authors.initials: D
authors.lastname: Huang
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China.
authors.forename: Weidi
authors.initials: W
authors.lastname: Shen
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China.
authors.forename: Juncheng
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China.
authors.forename: Kui
authors.initials: K
authors.lastname: Chen
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China.
authors.forename: Yuqing
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China.
authors.forename: Lili
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China.
authors.forename: Xiaochen
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Ouyang
authors.affiliation: Mental Health Institute of the Second Xiangya Hospital, National Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Hunan, People's Republic of China. Electronic address: zhaojingpingcsu@163.com.
authors.forename: Jingping
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Janssen Research and Development, Beijing, People's Republic of China. Electronic address: hlu29@its.jnj.com.
authors.forename: Huafei
authors.initials: H
authors.lastname: Lu
authors.affiliation: Mental Health Institute of the Second Xiangya Hospital, National Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Hunan, People's Republic of China. Electronic address: weihao57@163.com.
authors.forename: Wei
authors.initials: W
authors.lastname: Hao
mesh_terms: D000208:Acute Disease; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D044466:Asian People; D001499:Bayes Theorem; D004361:Drug Tolerance; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents
keywords: Antipsychotics; Chinese; Meta-analysis; Schizophrenia